Abstract
The main reason of #postmenopausalosteoporosis is high bone turnover
due to increased #osteoclasticaction. Strontium Ranelate is a new
drug that is used for the treatment of postmenopausal #osteoporosis. We
searched PubMed in May 2016 using the terms ‘Strontium ranelate’
for experimental study and review articles. The result from the studies
that we have conciliated show: Strontium ranelate enhances bone
resistance and increases the bone formation. Strontium ranelate has been
shown to increase bone apposition rates and bone mineral density
while maintaining the quality of bone mineral; but it has no effect on
#mineralization. Evidence from in vitro and in vitro studies present
the evidence that strontium ranelate is able to inhibit the osteoclasts
resorbing activity, decreased osteoclastic differentiation (Prevention
of
differentiation of blood #monocyte and pre-osteoclasts into osteoclasts)
and increase apoptosis of osteoclasts.
For more articles on BJSTR Journals please click here: https://biomedres.us/
For more Biomedical Intervention Articles on BJSTR
Strontium Ranelate Using for the Treatment of Postmenopausal #Osteoporosis by Amin Bigham-Sadegh in BJSTR
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.